Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2008-04-22
2008-04-22
Haddad, Maher M. (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S069100, C435S325000, C435S252300, C435S320100, C536S023500
Reexamination Certificate
active
07361463
ABSTRACT:
The present invention provides hypoxia inducible factor alpha muteins, DNA sequences encoding these hypoxia inducible factor alpha muteins, recombinant DNA molecules containing those DNA sequences operatively linked to expression control sequences and capable of inducing expression of an hypoxia inducible factor alpha muteins, hosts transformed with those recombinant DNA molecules, pharmaceutical compositions containing hypoxia inducible factor alpha muteins and methods of using those compositions to treat hypoxia and ischemic related tissue damage.
REFERENCES:
patent: 5882914 (1999-03-01), Semenza
patent: 6124131 (2000-09-01), Semenza
patent: 6222018 (2001-04-01), Semenza
patent: 6403764 (2002-06-01), Dubaquie et al.
patent: 2002/0048794 (2002-04-01), Poellinger et al.
patent: WO 0010578 (2000-03-01), None
patent: WO 02/12326 (2002-02-01), None
Attwood TK. Genomics. The Babel of bioinformatics. Science. 290(5491):471-473, 2000.
Burgess, et al. Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue. J Cell Biol. 111:2129-2138, 1990.
Metzler et al. Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28, Nat Struc Biol. 4(7):527-531, 1997.
Skolnick et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends Biotechnol. 18(1):34-9, 2000.
Lazar E et al., Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Mol Cell Biol. 8:1247-1252, 1988.
Mountain A. Gene therapy: the first decade. Trends Biotechnol. Mar. 2000;18(3):119-28.
Ivan et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001 Apr. 20; 292(5516): 464-8. Epub 2001 Apr. 5.
GenBank Accession No. BAB70608 (Oct. 23, 2001).
GenBank Accession No. BAB69689 (Jan. 18, 2002).
GenBank Accession No. BAA34234 (Oct. 11, 2001).
M. Ivan, W. G. Kaelin,Curr. Opin. Gen. and Dev.Nov. 27, 2001.
JelkmannPhysiol. Rev.72:449-489, 1992.
White et al.,Circ. Res. 71:1490-1500, 1992.
Wolfe et al.,Eur. J. Biochem. 135:405-412, 1983.
Semenza,Hematol. Oncol. Clinics N. Amer. 8:863-884, 1994.
Goldberg & Schneider, J.Biol. Chem. 269:4355-4359, 1994.
Semenza et al.,J. Biol. Chem. 269:23757-23763, 1994.
Wang & Semenza,Proc. Natl. Acad. Sci. USA 90:4304-4308, 1993.
Wang, G.L., and Semenza, G.L.,Blood. 82:3610-5 (1993).
Jiang, B.H., et al.,J. Biol. Chem. 272:19253-19260, 1997.
Semenza, G.L., et al.,Kid. Int. 51:553-555, 1997.
Jiang, B.H., et al.,Am J. Physiol. 271:C1172-C1180, 1996.
Jiang, B.-H., et al.,J. Biol. Chem. 271:17771-17778, 1996.
G. Semenza,Annu. Rev. Cell Dev. Biol.15, 551-578 (1999).
R. Wenger,J Exper Biol203, 1253-1263 (2000).
G. Semenza,Cell98, 281-4 (1999).
H. Zhu, F. Bunn,Resp. Phys.115, 239-247 (1999).
C. E. Stebbins, W. G. Kaelin, N. P. Pavletich,Science284, 455-461 (1999).
M. Ohh, et al.,Nature Cell Biology2, 423-427 (2000).
T. Kamura, et al.,Proc. Natl. Acad. Sci.(USA) 97, 10430-10435 (2000).
M. Cockman, et al.,J Biol Chem275, 25733-41 (2000).
K. Tanimoto, Y. Makino, T. Pereira, L. Poellinger,EMBO J19, 4298-4309 (2000).
P. Maxwell, et al.,Nature399, 271-5 (1999).
R. Deshaies,Annu Rev Cell Dev Biol15, 435-67 (1999).
D. Chowdary, J. Dermody, K. Jha, H. Ozer,Mol Cell Biol14, 1997-2003 (1994).
V. Srinivas, L. Zhang, X. Zhu, J. Caro,Biochem Biophys Res Commun260, 557-61 (1999).
C. Pugh, J. O'Rourke, M. Nagao, J. Gleadle, P. Ratcliffe,J Biol Chem272, 11205-14 (1997).
K. I. Kivirikko, J. Myllyharju, MatrixBiology16, 359-368 (1998).
O. Iliopoulos, A. Kibel, S. Gray, W. G. Kaelin,Nature Medicine1, 822-826 (1995).
Y. Takahashi, S. Takahashi, Y. Shiga, T. Yoshimi, T. Miura,J Biol Chem275, 14139-46 (2000).
M. Bickel, et al.,Hepatology28, 404-11 (1998).
T. Franklin, W. Morris, P. Edwards, M. Large, R. Stephenson,Biochem J353, 333-338 (2001).
L. Friedman, et al.,Proc Natl Acad SciU S A 97, 4736-41 (2000).
International Search Report for PCT/US02/08946, mailed Sep. 23, 2002.
Masson, et al. Eur. Mol. Bio. Org., 201, 5195-5206, Sept. 2001.
Ivan Mircea
Kaelin, Jr. William G.
Dana Farber Cancer Institute, Inc.
Elrifi Ivor R.
Haddad Maher M.
Kozakiewicz Cynthia
Mintz Levin Cohn Ferris Glovsky and Popeo PC
LandOfFree
Muteins of hypoxia inducible factor alpha and methods of use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Muteins of hypoxia inducible factor alpha and methods of use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Muteins of hypoxia inducible factor alpha and methods of use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2780715